X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Dr. Reddys with Abbott India - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

DR. REDDYS LAB vs ABBOTT INDIA - Comparison Results

DR. REDDYS LAB    Change

Dr. Reddy's is a leading pharmaceutical company in the country with presence across the value chain. While the global generics business accounted for 69% of total revenues in FY12, the PSAI business (Pharma Services and Active Ingredients - PSAI) con... More

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    DR. REDDYS LAB ABBOTT INDIA DR. REDDYS LAB/
ABBOTT INDIA
 
P/E (TTM) x 31.5 40.2 78.4% View Chart
P/BV x 3.4 10.3 32.7% View Chart
Dividend Yield % 0.8 0.7 116.8%  

Financials

 DR. REDDYS LAB   ABBOTT INDIA
EQUITY SHARE DATA
    DR. REDDYS LAB
Mar-18
ABBOTT INDIA
Mar-18
DR. REDDYS LAB/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs2,7886,110 45.6%   
Low Rs1,9023,996 47.6%   
Sales per share (Unadj.) Rs860.81,552.2 55.5%  
Earnings per share (Unadj.) Rs57.1188.8 30.2%  
Cash flow per share (Unadj.) Rs122.0196.4 62.1%  
Dividends per share (Unadj.) Rs20.0055.00 36.4%  
Dividend yield (eoy) %0.91.1 78.4%  
Book value per share (Unadj.) Rs757.7796.6 95.1%  
Shares outstanding (eoy) m165.9121.25 780.8%   
Bonus/Rights/Conversions ESOP--  
Price / Sales ratio x2.73.3 83.7%   
Avg P/E ratio x41.126.8 153.5%  
P/CF ratio (eoy) x19.225.7 74.7%  
Price / Book Value ratio x3.16.3 48.8%  
Dividend payout %35.029.1 120.3%   
Avg Mkt Cap Rs m389,034107,376 362.3%   
No. of employees `00023.53.3 708.1%   
Total wages/salary Rs m32,1493,937 816.6%   
Avg. sales/employee Rs Th6,070.89,929.3 61.1%   
Avg. wages/employee Rs Th1,366.61,185.1 115.3%   
Avg. net profit/employee Rs Th402.51,207.7 33.3%   
INCOME DATA
Net Sales Rs m142,81032,985 433.0%  
Other income Rs m1,5521,170 132.7%   
Total revenues Rs m144,36234,155 422.7%   
Gross profit Rs m23,5125,245 448.3%  
Depreciation Rs m10,772162 6,653.5%   
Interest Rs m78838 2,062.8%   
Profit before tax Rs m13,5046,215 217.3%   
Minority Interest Rs m00-   
Prior Period Items Rs m3440-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m4,3802,203 198.8%   
Profit after tax Rs m9,4684,012 236.0%  
Gross profit margin %16.515.9 103.5%  
Effective tax rate %32.435.4 91.5%   
Net profit margin %6.612.2 54.5%  
BALANCE SHEET DATA
Current assets Rs m104,98422,655 463.4%   
Current liabilities Rs m68,9386,681 1,031.9%   
Net working cap to sales %25.248.4 52.1%  
Current ratio x1.53.4 44.9%  
Inventory Days Days7465 114.8%  
Debtors Days Days10429 355.3%  
Net fixed assets Rs m104,385835 12,494.2%   
Share capital Rs m830213 390.6%   
"Free" reserves Rs m124,88616,715 747.1%   
Net worth Rs m125,71616,928 742.7%   
Long term debt Rs m25,0890-   
Total assets Rs m225,44324,162 933.1%  
Interest coverage x18.1163.7 11.1%   
Debt to equity ratio x0.20-  
Sales to assets ratio x0.61.4 46.4%   
Return on assets %4.516.8 27.1%  
Return on equity %7.523.7 31.8%  
Return on capital %9.736.9 26.3%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m72,623369 19,705.6%   
Fx outflow Rs m18,9163,807 496.9%   
Net fx Rs m53,707-3,438 -1,562.1%   
CASH FLOW
From Operations Rs m18,0301,527 1,180.7%  
From Investments Rs m-14,883-2,148 692.7%  
From Financial Activity Rs m-4,440-1,024 433.5%  
Net Cashflow Rs m-1,236-1,646 75.1%  

Share Holding

Indian Promoters % 25.5 0.0 -  
Foreign collaborators % 0.0 75.0 -  
Indian inst/Mut Fund % 5.4 7.9 68.4%  
FIIs % 35.3 0.1 35,300.0%  
ADR/GDR % 18.5 0.0 -  
Free float % 15.3 17.1 89.5%  
Shareholders   75,885 18,270 415.4%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare DR. REDDYS LAB With:   DR. DATSONS LABS  STRIDES SHASUN LTD  FULFORD INDIA  ALKEM LABORATORIES  AJANTA PHARMA  

Compare DR. REDDYS LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Slumps Over 275 Points; Realty and Banking Stocks Witness Selling(Closing)

After trading on a volatile note throughout the day, share markets in India witnessed selling pressure during the closing hours and ended the day in red.

Related Views on News

ABBOTT INDIA Announces Quarterly Results (1QFY19); Net Profit Up 70.8% (Quarterly Result Update)

Aug 20, 2018 | Updated on Aug 20, 2018

For the quarter ended June 2018, ABBOTT INDIA has posted a net profit of Rs 824 m (up 70.8% YoY). Sales on the other hand came in at Rs 8 bn (up 18.2% YoY). Read on for a complete analysis of ABBOTT INDIA's quarterly results.

DR. REDDYS LAB Announces Quarterly Results (1QFY19); Net Profit Up 614.9% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, DR. REDDYS LAB has posted a net profit of Rs 5 bn (up 614.9% YoY). Sales on the other hand came in at Rs 37 bn (up 12.1% YoY). Read on for a complete analysis of DR. REDDYS LAB's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

Biocon: US Pricing Pressure Takes Toll (Quarterly Results Update - Detailed)

Feb 2, 2018

Pricing pressure in the US and costs of the Malaysian facility hit Biocon's profits in the third quarter.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

DR. REDDYS LAB SHARE PRICE


Sep 21, 2018 (Close)

TRACK DR. REDDYS LAB

  • Track your investment in DR. REDDYS LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

DR. REDDYS LAB 5-YR ANALYSIS

COMPARE DR. REDDYS LAB WITH

MARKET STATS